Peripheral Edema Due To Chronic Heart Failure — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for peripheral edema due to chronic heart failure. 17 active patents protecting 4 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

4
Approved drugs
17
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Peripheral Edema Due To Chronic Heart Failure

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Searle/Pfizer) 13 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating peripheral edema due to chronic heart failure. Each bar = one year. Y-axis scaled to peak year (8 patents).

4
34
8
36
3
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Aldactone
spironolactone
 Generic (originally Searle/Pfizer) 8 50 — 2036-10-28
Bumex
BUMETANIDE
 — 4 70 — 2040-12-04
Lasix
furosemide
 Generic (originally Hoechst AG) 4 66 — 2034-04-03
Microzide
hydrochlorothiazide
 Generic (originally Merck) 1 75 — 2044-01-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12370168 Lasix method of use 75 2034-04-03
11260038 Bumex method of use 75 2040-12-04
12329731 Bumex method of use 75 2040-12-04
11878022 Microzide method of use 75 2044-01-23
12558330 Bumex method of use 75 2045-05-14
11433044 Lasix method of use 70 2034-04-03
9884039 Lasix method of use 70 2034-04-03
11395828 Aldactone method of use 70 2036-10-28
9757394 Aldactone method of use 62 2036-10-28
11123319 Bumex formulation 55 2040-12-04

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10493083 Aldactone formulation 42 2036-10-28
10624906 Aldactone formulation 42 2036-10-28
10888570 Aldactone formulation 42 2036-10-28
10660907 Aldactone formulation 42 2036-10-28
11491166 Aldactone formulation 50 2036-10-28
11389461 Aldactone formulation 50 2036-10-28
10272064 Lasix formulation 50 2034-04-03
11123319 Bumex formulation 55 2040-12-04
9757394 Aldactone method of use 62 2036-10-28
11395828 Aldactone method of use 70 2036-10-28

Related